Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D93YJK
|
|||
| Drug Name |
LY 3541105
|
|||
| Synonyms |
DACRA QW II
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66] | Phase 1 | [1] | |
| Company |
Lilly
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Calcitonin receptor (CALCR) | Target Info | Agonist | [2] |
| Islet amyloid polypeptide (IAPP) | Target Info | Agonist | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Osteoclast differentiation | ||||
| NetPath Pathway | RANKL Signaling Pathway | |||
| Reactome | G alpha (s) signalling events | |||
| Calcitonin-like ligand receptors | ||||
| WikiPathways | GPCRs, Class B Secretin-like | |||
| RANKL/RANK Signaling Pathway | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05380323) A Phase 1, Randomized, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and PK of LY3541105 Following Single Doses in Healthy/Overweight Participants and Multiple Doses in Overweight Participants. U.S.National Institutes of Health. | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.